Immuron Limited has seen significant sales growth in the past year, with global annual sales reaching AUD$7.3 million, a 49% increase from the previous year. The June 2025 quarter alone saw sales of AUD$2.0 million, up 55% from the prior year. In Australia, annual sales reached AUD$5.2 million, a 40% increase, with the June 2025 quarter seeing a 58% growth. In North America, annual sales reached AUD$2.0 million, a remarkable 76% increase, with the June 2025 quarter reaching AUD$0.5 million, up 49% from the prior year. The company attributes this success to the popularity of their product Travelan®, an over-the-counter immune supplement targeting pathogenic bacteria in the gastrointestinal tract. CEO Steven Lydeamore expressed excitement over the record sales and outlined plans for further growth in FY26, including investment in North America and continued momentum in Australia. Travelan® is a proven product that reduces the risk of traveler’s diarrhea by preventing colonization of diarrhea-causing bacteria.

Read more at GlobeNewswire: FY25 global sales exceed projection, up 49% on